These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33766150)

  • 1. Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II report.
    Flint AJ; Bingham KS; Neufeld NH; Alexopoulos GS; Mulsant BH; Rothschild AJ; Whyte EM; Voineskos AN; Marino P; Meyers BS;
    Psychol Med; 2021 Mar; ():1-7. PubMed ID: 33766150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study.
    Flint AJ; Rothschild AJ; Whyte EM; Alexopoulos GS; Mulsant BH; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Meyers BS;
    Am J Geriatr Psychiatry; 2021 Jul; 29(7):645-654. PubMed ID: 33268022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.
    Men X; Marshe V; Elsheikh SS; Alexopoulos GS; Marino P; Meyers BS; Mulsant BH; Rothschild AJ; Voineskos AN; Whyte EM; Kennedy JL; Flint AJ; Müller DJ
    Neuropsychobiology; 2023; 82(3):168-178. PubMed ID: 37015192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Alexopoulos GS; Rudorfer MV; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Mulsant BH;
    JAMA; 2019 Aug; 322(7):622-631. PubMed ID: 31429896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial.
    Flint AJ; Bingham KS; Alexopoulos GS; Marino P; Mulsant BH; Neufeld NH; Rothschild AJ; Voineskos AN; Whyte EM; Meyers BS;
    J Psychiatr Res; 2023 Jan; 157():285-290. PubMed ID: 36535116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.
    Bingham KS; Rothschild AJ; Mulsant BH; Whyte EM; Meyers BS; Banerjee S; Szanto K; Flint AJ;
    J Clin Psychiatry; 2017; 78(8):1149-1154. PubMed ID: 28445632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of white matter microstructure with psychomotor disturbance and relapse in remitted psychotic depression.
    Bingham KS; Calarco N; Dickie EW; Alexopoulos GS; Butters MA; Meyers BS; Marino P; Neufeld NH; Rothschild AJ; Whyte EM; Mulsant BH; Flint AJ; Voineskos AN
    J Affect Disord; 2023 Aug; 334():317-324. PubMed ID: 37149056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study.
    Song J; Mulsant BH; Sanches M; Alexopoulos GS; Marino P; Meyers BS; Rothschild AJ; Voineskos AN; Whyte EM; Flint AJ; Gerretsen P;
    J Affect Disord; 2023 Mar; 325():29-34. PubMed ID: 36592671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).
    Meyers BS; Flint AJ; Rothschild AJ; Mulsant BH; Whyte EM; Peasley-Miklus C; Papademetriou E; Leon AC; Heo M;
    Arch Gen Psychiatry; 2009 Aug; 66(8):838-47. PubMed ID: 19652123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Mulsant BH; Rudorfer MV; Marino P;
    BMC Psychiatry; 2013 Jan; 13():38. PubMed ID: 23351522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.
    Voineskos AN; Mulsant BH; Dickie EW; Neufeld NH; Rothschild AJ; Whyte EM; Meyers BS; Alexopoulos GS; Hoptman MJ; Lerch JP; Flint AJ
    JAMA Psychiatry; 2020 Jul; 77(7):674-683. PubMed ID: 32101271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).
    Østergaard SD; Rothschild AJ; Flint AJ; Mulsant BH; Whyte EM; Vermeulen T; Bech P; Meyers BS
    J Affect Disord; 2016 Jan; 190():111-114. PubMed ID: 26496016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilization treatment of remitted psychotic depression: the STOP-PD study.
    Bingham KS; Meyers BS; Mulsant BH; Rothschild AJ; Whyte EM; Banerjee S; Artis AS; Alexopoulos GS; Flint AJ;
    Acta Psychiatr Scand; 2018 Sep; 138(3):267-273. PubMed ID: 29959765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial.
    Ihaddadene RA; Alexopoulos GS; Marino P; Meyers BS; Mulsant BH; Neufeld NH; Rothschild AJ; Voineskos AN; Whyte EM; Flint AJ; Bingham KS;
    Psychiatry Res; 2024 Sep; 342():116192. PubMed ID: 39299145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectories of remitted psychotic depression: identification of predictors of worsening by machine learning.
    Banerjee S; Wu Y; Bingham KS; Marino P; Meyers BS; Mulsant BH; Neufeld NH; Oliver LD; Power JD; Rothschild AJ; Sirey JA; Voineskos AN; Whyte EM; Alexopoulos GS; Flint AJ;
    Psychol Med; 2024 Apr; 54(6):1142-1151. PubMed ID: 37818656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial.
    Flint AJ; Iaboni A; Mulsant BH; Rothschild AJ; Whyte EM; Meyers BS;
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):332-6. PubMed ID: 23642462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.
    Weissman J; Flint A; Meyers B; Ghosh S; Mulsant B; Rothschild A; Whyte E;
    Psychiatry Res; 2012 May; 197(3):221-6. PubMed ID: 22464991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.
    Østergaard SD; Meyers BS; Flint AJ; Mulsant BH; Whyte EM; Ulbricht CM; Bech P; Rothschild AJ;
    J Affect Disord; 2014 May; 160():68-73. PubMed ID: 24439830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.
    Bingham KS; Whyte EM; Meyers BS; Mulsant BH; Rothschild AJ; Banerjee S; Flint AJ;
    Am J Geriatr Psychiatry; 2015 Dec; 23(12):1270-1275. PubMed ID: 26560512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.